A subscription to JoVE is required to view this content. Sign in or start your free trial.
Chapters
- 00:04Title
- 00:11Introduction
- 01:23TRIP Vector and Proposed Mech for tkRNAi
- 02:45Co-incubation of Bacteria and Cancer Cells
- 05:56Representative Results
- 07:21Conclusion
For development of RNA interference (RNAi)-based therapies, a novel strategy was developed, transkingdom RNAi (tkRNAi). This technology uses non-pathogenic bacteria to produce and deliver therapeutic short hairpin RNA (shRNA) into target cells. Here, tkRNAi was successfully applied for reversal of classical ABCB1-mediated multidrug resistance (MDR) of cancer cells.
